The size of the Uterine Cancer Therapeutics Market in the Asia Pacific is expected to reach USD 4.42 Billion by 2027 from USD 3.20 Billion in 2022, growing at a CAGR of 6.67% during the forecast period 2022 to 2027.
Uterine cancer is one of the most commonly prevailing malignant tumors that start in the uterus cells and spread to other parts of the body. Uterine cancer is mainly of two types such as uterine sarcoma and endometrial carcinoma. As a result, more therapies have evolved to manage uterine cancer types, including surgery, chemotherapy, radiation therapy, immunotherapy, and hormone therapy.
Increasing focus of government to provide early detection programs for uterine cancer, rising provision of optimal therapeutic strategies to treat uterine cancer, growing economy, and increasing advancements in the cancer screening & treatment methods are driving the growth of the Asia-Pacific Uterine Cancer Therapeutics Market.
However, the high cost of the treatment solutions, limited access to advanced cancer therapies in some developing regions are expected to restrain the growth of the Uterine Cancer Therapeutics Market.
This research report on the APAC Uterine Cancer Therapeutics Market is segmented & sub-segmented into the following categories:
Geographically, the Asia Pacific uterine cancer therapeutics market is one of the fastest-growing regions globally. Therefore, the APAC Uterine cancer therapeutics market is expected to grow at a significant CAGR during the forecast period. The regional market growth is attributed to the improving healthcare infrastructure, rising healthcare spending, and increasing knowledge of uterine disorders and accessible therapeutics. In addition, subsequent technology developments, drug development innovation, and favorable government policies are the primary factors driving the market growth. In addition, following research into the disease’s vital nature and impact, healthcare providers and governments in the Asia Pacific region are launching awareness campaigns in several areas.
In APAC, the Indian uterine cancer therapeutics market is expected to register a promising CAGR during the forecast period. India has a National Cancer Control Program established back then; it has contributed to the growth of Regional Cancer Centers (RCCs), oncology departments in medical institutes, and financial assistance for the procurement of teletherapy machines. Furthermore, cancer awareness initiatives are being held to educate women about the seriousness of uterine cancer. The risk of uterine cancer is higher in women over the age of 50. It has also been revealed that cervical cancer is more common in developing countries such as India and China, accounting for 80 percent of all cases.
The Chinese uterine cancer therapeutics market is anticipated to account for a promising share in the APAC market during the forecast period. Technological advancements in the healthcare sector, favorable reimbursement policies, and availability of advanced healthcare facilities. According to the Journal of Gynecological Oncology 2020, endometrial cancer is a common gynecologic malignancy in Japan, with the highest prevalence among individuals with gynecologic malignant tumors. In 2017, the age-adjusted death rate for endometrial cancer in Japan was 2.0.
The Australian uterine cancer therapeutics market is forecasted to be growing at a prominent CAGR from 2022 to 2027. According to Cancer Australia in 2019. As a result of the above causes, the segment is predicted to develop in the following years. Uterine cancer claimed the lives of 527 people in Australia, according to Cancer Australia. In 2019, it was estimated that 562 people died. Furthermore, according to the research, a female's probability of dying from uterine cancer is 1 in 205. Moreover, governments in several Asia Pacific regions are promoting public awareness campaigns. As a result, the market is expected to grow fast over the forecast period, owing to the government’s and healthcare providers’ increased focus.
KEY MARKET PLAYERS:
A few of the notable companies operating in the APAC uterine cancer therapeutics market profiled in this report are Abbott Laboratories, Ariad Pharmaceuticals, Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co., Inc., Novartis AG, Sanofi, Siemens Healthcare GmbH and Takeda Pharmaceutical Company Ltd.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com